3Vote!
PR News Wire (Free subscription) | yesterday
SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will...
4Vote!
Medical News Today (Free subscription) | yesterday
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic...
5Vote!
Medical News Today (Free subscription) | yesterday
ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company is pleased to announce the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE).
3Vote!
Sify (Free subscription) | yesterday
ImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second potential cancer-treatment from the company for $1 million upfront.
3Vote!
PR News Wire (Free subscription) | 19/11/2009
BLAUVELT, N.Y., Nov. 19 /PRNewswire/ -- Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, responds to a press release issued on November 17 by Biropharma Kft, discrediting the Hungarian company for making false and self-serving statements about its U.S. competitor American BioSciences.
3Vote!
Xconomy (Free subscription) | 19/11/2009
Waltham, MA-based ImmunoGen (NASDAQ: IMGN) said today that Amgen has purchased a second license to develop a treatment that uses ImmunoGen’s technology for linking targeted antibodies to cell-killing agents that make them more potent. ImmunoGen will get $1 million upfront and could receive $34 million worth of milestone payments over time if Amgen is successful [...]
3Vote!
PR News Wire (Free subscription) | 19/11/2009
COPENHAGEN, Nov. 19 /PRNewswire/ -- Danish Prince Joachim inaugurated the DONG Energy and Inbicon cellulosic ethanol plant in Kalundborg, Denmark, on Wednesday, November 18. The facility is one of the world's first and largest 2nd generation ethanol demonstration biorefineries. Genencor's Accellerase enzymes are used in the plant's innovative process for converting straw to fuel. Genencor, a Division...
3Vote!
Business Wire (Free subscription) | 19/11/2009
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the second such license to be taken by Amgen –...
3Vote!
PR News Wire (Free subscription) | 19/11/2009
ABBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstCall/ -- The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the second consecutive year. The Deal honored Abbott as its Most Admired Dealmaker in pharma/biotech for the most effective strategic use of acquisitions and divestitures since January 2006.
3Vote!
StreetInsider.com News Articles (Free subscription) | 19/11/2009
Notable 52-week Highs on the NYSE: Cardinal Health, Inc. (NYSE: CAH) - Hit $31.77. UBS initiated coverage with a Buy rating on Cardinal. Donaldson Company Inc. (NYSE: DCI) - touched $45.09. The company reported Q110 earnings about the Street estimates today. IMS Health Inc. (NYSE: RX) - reached $21.65 King Pharmaceuticals Inc. (NYSE: KG) - hit $11.88. May be benefitting from mixed ZymoGenetics ratings...
Explore : Cardinal Health,
Donaldson Company,
Drug Manufacturers,
Environment,
Financial Services,
Health Care Services,
Health Industries,
IMS Health Inc.,
King Pharmaceuticals,
Merck,
Money,
New York Stock Exchange,
NYSE Group,
Software,
Software and services,
Stock exchange,
ZymoGenetics
7Vote!
Green Car Congress (Free subscription) | 19/11/2009
Amyris engineers microbes to convert sugar to hydrocarbon fuels. Micrograph of fermentation fluids from production of Amyris Renewable Diesel (Nov 2007). Source: Amyris. Click to enlarge. Embraer, General Electric, and Amyris Biotechnologies, a synthetic biology company focused on developing renewable...
3Vote!
Market Watch (Free subscription) | 19/11/2009
BOSTON (MarketWatch) -- Allergan Inc. and Medicis Pharmaceutical Corp. led drug stocks lower early Thursday as shares of the dermatology-products makers fell on news that a new bill unveiled by Senate Democrats would levy a 5% excise tax on cosmetic procedures. The NYSE Arca Pharmaceutical Index and the NYSE Arca Biotechnology Index were both down 1.4% at 298.94 and 872.60, respectively. Shares of...
3Vote!
PR News Wire (Free subscription) | 19/11/2009
BEDFORD, Mass., Nov. 19 /PRNewswire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE), a global provider of imaging and biometrics software, today announced it will showcase its new AccuRad ImageShare Platform, a standards-based cross-enterprise image sharing platform for health information exchange (HIE), at the RSNA 2009 Scientific Assembly and Annual Meeting. Aware will also participate in the Integrating...
3Vote!
PR News Wire (Free subscription) | 19/11/2009
MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.
Videos